Molecular Classification
Other (not a protein, receptor, enzyme, etc.; refers to small molecules/chemicals with cytotoxic activity)
Other Names
DNA alkylator, DNA crosslinker, Alkylating antineoplastic agent, Bifunctional alkylating agent
Disease Roles
Cancer (primary use in oncology for treatment of various malignancies)Other roles are limited and primarily research-based

Alkylating agent causing DNA crosslinking Overview

Alkylating agents causing DNA crosslinking are a class of chemotherapeutic drugs that exert their cytotoxic effects by transferring alkyl groups onto nucleophilic sites within cellular macromolecules—most importantly the nitrogenous bases in genomic DNA. Bifunctional variants can form covalent bridges either within one strand or between both strands ("crosslinks"), which block essential processes such as replication and transcription. This leads ultimately to cell cycle arrest and apoptosis if repair mechanisms fail. These compounds have been foundational in cancer therapy since their introduction following observations from chemical warfare research during World War II. While highly effective against rapidly dividing cells such as those found in many cancers, they lack specificity for malignant cells over normal proliferative tissues—a limitation reflected in their significant side effect profiles including bone marrow suppression, gastrointestinal injury, infertility risks, and potential induction of secondary cancers through mutagenesis[1][2][3].

Mechanism of Action

Covalent binding to nucleophilic sites on DNA bases—primarily the N7 position on guanine—resulting in the formation of intra-strand and inter-strand crosslinks[1][2][3]. Crosslinks prevent proper separation and replication/transcription of the double helix, leading to replication arrest and cell death if unrepaired. Some also form covalent bonds between DNA and proteins ("DNA-protein crosslinks")[1].

Biological Functions

Induction of cell death (apoptosis)
Inhibition of cell division (cell cycle arrest)
Induction of DNA damage response

Disease Associations

Cancer (primary use in oncology for treatment of various malignancies)
Other roles are limited and primarily research-based

Safety Considerations

  • Myelosuppression/hematopoietic toxicity
  • Gastrointestinal toxicity (nausea/vomiting/mucositis)
  • Gonadal toxicity/infertility risk
  • Secondary malignancies due to mutagenesis/carcinogenesis risk from off-target effects[3]
  • Each drug has its own specific side effect profile.

Interacting Drugs

Cyclophosphamide
Melphalan
Busulfan
Nitrogen mustards (e.g., mechlorethamine)
Carmustine
Cisplatin and other platinum compounds

Associated Biomarkers

Biomarker
O6-methylguanine-DNA methyltransferase (MGMT) expression can predict resistance/sensitivity to some alkylators.
Metallothionein levels may correlate with resistance to platinum-based agents[3].
These are context-dependent rather than universal.